How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
Related Articles
ICML 2025 | What do the initial results from the LOTIS-7 trial suggest for loncastuximab tesirine plus glofitamab in R/R DLBCL?
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL? | Lymphoma Hub
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
ICML 2025 | Results from EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated DLBCL
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine…
ICML 2025 | What do the initial results from the LOTIS-7 trial suggest for loncastuximab tesirine plus glofitamab in R/R DLBCL?
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?
During EHA 2025, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the…
EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL? | Lymphoma Hub
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL
On June 18, 2025, the FDA approved tafasitamab in combination with rituximab plus lenalidomide for the treatment of adult patients with R/R FL.
EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?
During EHA 2025, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the…
18th International Conference on Malignant Lymphoma (ICML) congress coverage
Catch up on our live social media coverage of lymphoma and CLL from the 18th International Conference on Malignant Lymphoma.
EHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are eligible for ASCT?
During EHA 2025, the Lymphoma Hub was pleased to speak to Marek TrnÄ›ný, Charles University, Prague, CZ, who discussed the significance of the first efficacy…